Disease relevance of RPL23A

• The vaccinia virus E3L protein interacts with SUMO-1 and ribosomal protein L23a in a yeast two hybrid assay [1].
• Expression of rp L23a is also reduced in human melanoma cells treated with human leukocyte (IFN-alpha) and immune (IFN-gamma) interferons, but not by growth inhibition resulting from serum starvation [2].
• Clones corresponding to enolase, cyclophilin, ribosomal protein L23a, and an Hsp70 family protein were isolated with sIgA from a patient with amebic liver abscess [3].

High impact information on RPL23A

• The mechanism underlying inhibition in rp L23a expression in IFN-beta-treated cells may involve antisense rp L23a RNA [2].
• Suppression of human ribosomal protein L23A expression during cell growth inhibition by interferon-beta [2].
• The mRNA levels of rp L23a and growth are diminished in a variety of human tumor cell lines following treatment with human fibroblast interferon, interferon-beta (IFN-beta) [2].
• The intron-containing RPL23A gene was mapped to cytogenetic band 17q11 by fluorescence in situ hybridization [4].
• In adult tissues, the RPL23A transcript is dramatically more abundant in pancreas, skeletal muscle, and heart, while much less abundant in kidney, brain, placenta, lung, and liver [4].

Biological context of RPL23A

• The open reading frame encodes a polypeptide of 156 amino acids, which is absolutely conserved with the rat RPL23A protein [4].
• The presence of the RPL23A pseudogene was shown in canid B chromosomes [5].

Analytical, diagnostic and therapeutic context of RPL23A

• Sequence analysis indicates that mda-20 is human ribosomal protein L23a (rp L23a) [2].

References